Abstract Body

Background

Long-acting (LA-) injectable cabotegravir-rilpivirine (CAB/RPV) can achieve viral suppression (VS) in PWH with poor adherence to daily ART and persistent viremia. While current DHHS guidelines recommend this indication for CAB/RPV on a case-by-case basis, the FDA is requiring a randomized trial for approval. Our objective was to project the clinical impact of delaying CAB/RPV implementation in the US for PWH with persistent viremia while awaiting further trial data.

Methods

Using the CEPAC microsimulation model, we considered 2 treatment strategies in a prevalent cohort of PWH with persistent viremia and no prior NNRTI or INSTI resistance: 1) standard daily INSTI-based oral ART, and 2) bi-monthly CAB/RPV injections. Both are coupled with social service supports to improve engagement in care. We evaluated different scenarios of CAB/RPV uptake: 1) current practice with 99% on oral ART, 1% on CAB/RPV; 2) 100% uptake of CAB/RPV after 0 to 5y of delay; 3) 2 trial types: a single-arm 1y demonstration project with 5%/y uptake thereafter, and a 3y RCT, with 20%/y uptake thereafter; and 4) immediate 3%/y uptake of CAB/RPV for 5y. We modeled a prevalent cohort of 50,000 PWH with persistent viremia in the US and added 1,500 new people yearly. Model outcomes were person-years (PY) with VS, PY viremic, and deaths, all reported at 5y. Model inputs from published studies included: mean age 46y, mean initial CD4 count 150/µL, 6m VS of 23% for oral ART and 65% for CAB/RPV. We varied key parameters in sensitivity analysis.

Results

Current practice leads to 67,730 PY with VS (of 322,500 total PY) and 29,800 deaths (of 57,500 PWH) at 5y (Table). 100% uptake of CAB/RPV with no delay increases PY with VS by 49,800 and averts 6,800 deaths (23% of deaths). Each year of delay to 100% uptake leads to ~9,960 fewer PY with VS and ~1,350 more deaths. Compared to current practice, a single-arm demonstration project yields 2,490 more PY with VS and 330 fewer deaths, while an RCT produces 2,460 more PY with VS and 200 fewer deaths. With immediate uptake of CAB/RPV, similar gains (~2,400 PY with VS) would be achieved at only 3%/y uptake. In sensitivity analysis, disengagement from care is the most influential parameter affecting survival.

Conclusions

LA-CAB/RPV for PWH with persistent viremia in the US would increase VS and life expectancy. Each year of delayed uptake would substantially increase years of viremia and mortality. Rapid implementation of CAB/RPV should be undertaken, even while awaiting RCT results.